Baseline characteristics
| Trials providing information | ARNI | No. analysed (ARNI) | Control | No. analysed (Control) | |
| Age - years (SD) | 46 | 66.1 (9.8) | 9433 | 66.0 (9.7) | 9408 |
| Male sex - n (%) | 46 | 6214 (65.9) | 9433 | 6178 (66.0)) | 9358 |
| Female sex - n (%) | 46 | 3220 (34.1) | 9433 | 3194 (34.0) | 9358 |
| Mean body mass index (SD) | 10 | 29.0 (5.3) | 7600 | 29.0 (5.3) | 7611 |
| History of atrial fibrillation - n (%) | 6 | 2530 (34.7) | 7290 | 2610 (35.7) | 7301 |
| Diabetes - n (%) | 11 | 2757 (36.3) | 7578 | 2748 (36.2) | 7591 |
| Hypertension - n (%) | 15 | 6024 (77.8) | 7744 | 5995 (77.3) | 7751 |
| Previous heart failure - hospitalisation – n (%) | 5 | 3960 (56.3) | 7034 | 4050 (57.7) | 7044 |
| Previous myocardial infarction - n (%) | 6 | 2454 (33.7) | 7278 | 2417 (33.1) | 7287 |
| NYHA-class – n (%) | 26 | 8735 | 8335 | ||
| NYHA 1 | 291 (0.35) | 307 (0.37) | |||
| NYHA 2 | 5558 (66.7) | 5478 (65.7) | |||
| NYHA 3 | 2205 (26.5) | 2289 (27.4) | |||
| NYHA 4 | 257 (3.1) | 256 (3.1) | |||
| Heart failure classification – n (%) | 32 | 8694 | 8722 | ||
| Heart failure with reduced ejection fraction | 6025 | 6069 | |||
| Heart failure with midrange ejection fraction | 0 | 0 | |||
| Heart failure with preserved ejection fraction | 2669 | 2653 | |||
| Baseline medications – n (%) | |||||
| Beta-blockers | 10 | 6634 (85.8) | 7731 | 6608 (85.6) | 7716 |
| Diuretics | 8 | 6284 (82.9) | 7583 | 6291 (82.5) | 7618 |
| MRA | 9 | 3164 (41.3) | 7654 | 3353 (43.7) | 7667 |
| Pretrial ACE-I | 3 | 3363 (76.5) | 4396 | 3361 (76.0) | 4422 |
| Pretrial ARB | 3 | 1032 (23.5) | 4396 | 1068 (24.2) | 4422 |
| Pretrial ARB/ACE-I | 8 | 6936 (91.5) | 7583 | 6988 (92.0) | 7598 |
ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor blocker neprilysin inhibitor; MRA, mineralocorticoid-receptor antagonists; NYHA, New York Heart Association.